nos publications

notre dernier livre Découvrez notre dernier livre « Somatostatin analogues : From research to clinical practice », disponible ici

Filtres : Toutes les thématiques cardiologie orthopédie / infections inflammations Radionucléide Traitement uro-néfrologie TEP / TDM (Pet Scan) autres Toutes les années 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1992

Predictors of overall and disease free survival in metastatic castration resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy.
Sathekge M, Bruchertseifer F, Vorster M, Lawal I, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel F, Van de Wiele C, Morgenstern A. J Nucl Med 2020;61(1):62-69 PSMA expression on tumor neovasculature of solid tumors.
Van de Wiele C, Sathekge M, de Spiegeleer B, de Jonghe P, Debriyne P, Borms M, Beels L, Maes A. Histol Histopathol 2020; in press PSMA-targeting Positron Emission Emission Agents for imaging solid tumors other than non-prostate carcinoma: a systematic review
Van de Wiele C, Sathekge M, De Spiegleer B, de Jonghe P, Beels L, Maes A Int J Mol Sci 2019;20(19).pii:E4886.doi:10.3390/ijms20194886 FDG-PET/CT imaging of uterine cervical cancer recurrence in women with and without HIV infection
Lawal I, Ololade K, Popoola G, ANkrah A, Vorster M, Maes A, Mogkoro N, Van de Wiele C, Sathekge M Q J Nucl Med Mol Imaging 2019.may 8. doi:10.23736/S1824-4785.19.03156-X 68Ga-citrate PET/CT in tuberculosis: a pilot study.
Vorste M, Maes A, Van de Wiele C, Sathekge M. Q J Nucl Med Mol Imaging 2019; 63(1):48-55 Reversible myocardial perfusion defects in patients not suffering from obstructive epicardial coronary artery disease as assessed by coronary angiography: a review of the literature. Van de Wiele C, Rimbu A, Belhocine T, De Spiegeleer B, Sathekge M, Maes A. Q J Nucl Med Mol Imaging, 2018; 62: 6369-6383. 68Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on the differences between black and white South-Africans. Sathekge M, Lengana T, Maes A, Vorster M, Zeevaart J, Lawala I, Ebenhan T, Van de Wiele C. Eur J Nucl Med Mol Imaging 2018; 45: 226-234 68Ga-PSMA-HBED-CC PET/CT imaging in black versus white South-African patients with prostate carcinoma presenting with a low volume androgen-dependent biochemical recurrence: a prospective study. Lengana T, Van de Wiele C, Lawal I, Maes A, Ebehna T, Boshomonae T, Zeevaart J, ANkrah A, Mokgoro N, Vorster M, Sathekge M. Nucl Med Commun 2018; 39: 179-185 Screening of quorum sensing peptides for biological effects in neuronal cells. Janssens Y, Wynendaele E, Verbeke F, Debunne N, Gevaert B, Audenaert K, Van de Wiele C, De Spiegeleer B. Peptides 2018; 101: 150-156. Patient-specific lean-body mass can be estimated from limited-coverage computed tomography images. Devriese J, Beels L, Maes A, Van de Wiele C, Pottel H. Nucl Med Commun 2018; 39: 521-526. Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatotropin case. Bracke N, Janssens Y, Wynendaele E, Tack L, Maes A, Van de Wiele C, Sathekge M, De Spiegeleer B. Q J Nucl Med Mol Imaging 2018; doi: 10.23736/S1824-4785.18.03025-X. 68Ga-PSMA PET/CT repalicng bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Lengana T, Lawal I, Boshomane T, Popoola G, MOKOala K, Moshokoa E, Maes A, Mokgoror N, Van de Wiele C, Vorster M, Sathekge M.  Clin Genitourin Cancer 2018; 16: 392-401. Tuberculosis.ANkrah A, Glaudemans A, Maes A, Van de Wiele C, Dierckx R, Vorster M, Sathekge M. Semin Nucl Med 2018; 48: 108-130. Prognostic value of pre-treatment F-18 FDG PET metabolic metrics in patients with locally advanced carcinoma of the anus with and without HIV infection. Lawala I, Ankrah A, Mokoala K, Popoola G, Kaoma C, Maes A, Mokgoro N, Van de Wiele C, Sathekge M. Nuklearmedizin 2018; 57: 190-197. Impact of PET reconstruction protocols on quantification of lesions that fulfill the PERCIST criteria
Devriese J, Beels L, Maes A, Van de Wiele C, Pottel H EJNNMI PHys 2018; 7;(5)1: 35:10.1186/s40658-018-0235-6 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients.
Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart J, Maes A, Ebenhan T, Van de Wiele C Eur J Nucl Med Mol Imaging 2017, 44: 689-694. Metabolic and morphological measurements of subcutaneous and visceral fat and their relationship with disease stage and overall survival in newly diagnosed pancreatic adenocarcinoma. Van de Wiele C, Van Vlaenderen M, D'Huklst L, Delcourt A, Copin D, De Spiegeleer B, Maes A. Eur J Nucl Med Mol Imaging 2017; 44: 110-116. In vitro functional quality characterization of NOTA-modified somatropins. Bracke N, Han Y, Wynendaele E, Verbeke F, Xu X, Gevaert B, Maes A, Van de Wiele C, Sathekge M, De Saeger S, De Spiegeleer B Analytical Chemistry 2017, 89: 2764-2772. Peptides as quorum sensing molecules: measurement techniques and obtained levels in vitro and in vivo. Verbeke F, De Craemer S, Debunne N, Janssens Y, Wynendaele E, Van de Wiele C, De Spiegeleer B. Front Neurosci 2017; 12: 183.doi:10.3389/fnins.2017.00183 The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumour burden and therapy outcome in patients with Hodgkin Lymphoma. Lawal I, Nozipo E, Nyalame M, Lerwine H, Modiselle M, Ankrah A, Msomi A, Mokgor N, Boshomane T, Van de Wiele C, Sathekge M. Eur J Nucl Med Mol  Imaging 2017; 44: 2025-2033. FDG PET/CT findings in multifocal splenic lymphoma. Van de Wiele C, Verstreate K, Bourgeois S, Maes A. Hell J Nucl Med 2017, 20: 182-183. Stable metabolic disease on FDG-PET provides information on response to endocrine therapy for breast cancer Kruse V, Van de Wiele C, Maes A, Borms M, Van Belle S, Coquyt V Q J Nucl Med Mol Imaging, 2017; 61: 108-114 Gallium-68 PET: a powerful generator-based alternative to infection and inflammation imaging Vorster M, Maes A, Van de Wiele C, Sathekge M Semin Nucl Med 2016; 46: 436-447 18F-FDG PET/CT imaging for the assessment of the volume of the spleen Smeets P, Mees G, Ham H, Maes A, Verstraete K, Van de Wiele C Q J Nucl Med Mol Imaging, 2016; 60: 48-53. False positive axilary lymph nodes due to silicone adenitis on (18)F-FDG PET/CT in an oncological setting. D’Hulst L, Nicolaij D, Beels L, Gheysens O, Alaerts H, Van de Wiele C, Maes A. J Thorac Oncol 2016; 11(6):e73-75. Doi:10.1016/j.jtho.2016.01.001. Preclinical validation of automated dual-energy X-ray absorptiometry and computed tomography-based body composition measurements. Devriese J, Beels L, Van de Wiele C, Maes A, Gheysens O, Pottel H. Q J Nucl Med Mol Imaging 2016; 60: 40-47. Review of clinically accessible methods to determine lean body mass for normalization of standardized uptake values. Devriese J, Beels L, Maes A, Van de Wiele C, Gheysens O, Pottel H. Q J Nucl Med Mol Imaging 2016; 60: 1-11. Accuracy of bone SPECT/CT for identifying hardware loosening in patients that underwent lumbar fusion with pedicle screws. Hudyana H, Maes A, Vandenberghe T, Fidlers L, Sathekge M, Nicolai D, Van de Wiele C. Eur J Nucl Med Mol Imaging, 2016; 43: 349-354. Evaluation of CT-based SUV normalization Devriese J, Beels L, Maes A, Van de Wiele C, Pottel H. PMB, 2016, 61: 6369-6383. The quorum sensing peptides PrG, CSP and EDF promote angiogenesis and invasion of breast cancer cells in vitro Wynendaele E, Verbeke F, D’Hondt M, Hendrix A, Van de Wiele C, Burvenich C, Peremans K, De Wever O, Bracke M, De Spiegeleer B PLoS One 2015;10(3):e0119471.doi:10/1371/journal.pone.0119471. Quorum sensing peptides selectively penetrate the blood brain-barrier Wynendaele E, Verbeke F, Stalmans S, Gevaert B, Janssens Y, Van de Wiele C, Peremans K, Burvenich C, De Spiegeleer B. PLoS One, 2015; 10(11):e142071.doi:10.1371/journal.pone.014271. 99mTc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. Belhocine T, Blankenberg F, Karchova M, Stitt L, Vanderheyden JL, Hoeben F, Van de Wiele C. Eur J Nucl Med Mol Imaging, 2015, 42: 2083-2097. Reproducibility of intratumoral FDG distribution and of metabolic tumor volume in 18F-FDG PET Kruse V, Mees G, D’Asseler Y, Maes A, Borms M, Cocquyt V, Van de Wiele C Q J Nucl Med Mol Imaging 2015; 59: 462-468 PET/CT imaging of Tuberculosis with 68Ga-citrate. M Vorster, A Maes, C Van de Wiele, M Sathekge Mol Imaging Radionucl Ther 2015; 24: 42. Doi: 10.4274/mirt.24.01.09 Reproducibility of FDG PET based metabolic tumor volume measurements and their FDG distribution within Kruse V, Mees G, D’Asseler Y, Maes A, Borms M, Cocquyt V, Van de Wiele C Q J Nucl Med Mol Imaging 2015; 59: 462-468. PET AND SPECT imaging of Monocyte and Macrophage trafficking Van de Wiele C, Sathekge M, Maes A. Q J Nucl Med Mol Imaging, 2014, 58: 269-275. Effect of AIDS on women who have sex-determined issues Sathekge M, Maes A, Van de Wiele C, Dadachova E. Seminars in Nuclear medicine, 2014, 44: 489-498. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence: factors influencing the area under the ROC-curve Kruse V, Van de Wiele C, Maes A, Borms M, Pottel H, van Belle S, Coquyt V Nuklearmedizin 2014, 53: 131-138. Analytical characterization of NOTA-modified somatropins Bracke N, Wynendaele E, DHondt M, Haselberg R, Pauwels E, Van de Wiele C, De Spiegeleer B J Pharm Biomed Analysis, 2014; 96; 1-9. Personalized medicine in oncology, the potential role of nuclear medicine imaging C Van de Wiele, G Mees Curr Pharm Des, 2014; 20: 2231-2233 Effect of AIDS on women who have sex-determined issues Sathekge M, Maes A, Van de Wiele C, Dadachova E. Seminars in Nuclear medicine, 2014, 44: 489-498. Evaluating the possible role of 68Ga-citrate PET/CT in the characterization of indeterminate lung lesions Vorster M, Maes A, Jacobs A, Malefahlo S, Pottel H, Van de Wiele C, Sathekge M. Ann Nucl Med 2014; 28: 523-530. 68Ga-citrate PET/CT in tuberculosis: a pilot study Vorster M, Maes A, Van de Wiele C, Sathekge M. Q J Nucl Med Mol Imaging 2014, epub ahead of print. Nuclear medicine imaging for personalized medicine (editorial) C Van de Wiele, G Mees Curr Pharm Des, 2014; 20: 2231-2233. Radiolabeled probes targeting tumor hypoxia for personalized medicine G Mees, A Maes, M Sathekge, C Van de Wiele Curr Pharm Des, 2014, 20: 2308-2318. Pretreatment quantitative 99mTc-MAA SPECT/CT and FDG PET/CT VOI analysis of liver metastases: relationship with treatment response to SIRT C Van de Wiele, K Stellamans, E Brugman, G Mees, B De Spiegeleer, Y D’Asseler, A Maes Nuklearmedizin, 2013, 52: 21-27. Pharmacological activation of tumor hypoxia: a means to increase tumor FDG uptake? G Mees, R Dierckx, C Vangestel, D Laukens, N Van Damme, C Van de Wiele Mol Imaging 2013, 12: 49-58. SAM in FDG PET assessment of treatment response in colorectal liver metastases J Mertens, S Debruyne, N Van Damme, P Smeets, W Ceelen, R Troisi, S Laurent, K Geboes, M Peeters, I Goethals, C Van de Wiele Eur J Nucl Med Mol Imaging, 2013, 40:1214-1222. Quorumpeps database: chemical space and functionality of quorum-sensing peptides E Wynendaele, A Bronselaar, J Nielandt, M D’Hondt, S Stalmans, N Bracke, C Van de Wiele, G De Tré, B De Spiegeleer NARS, 2013, 41: D655-659. Serum tumor markers and PET-CT imaging for tumor recurrence detection V Kruse, V Cocquyt, M Borms, A Maes, C Van de Wiele Ann Nucl Med, 2013, 27:97-104. FDG PET/CT in HIV and TB M Sathekge, A Maes, C Van de Wiele Sem Nucl Med 2013, 43: 349-366. Ga-68: a systematic review of its non-oncological applications Vorster M, Maes A, Van de Wiele C, Sathekge M Nucl Med Commun: 2013; 34: 834-854. Predictive and prognostic value of metabolic tumor volume and total lesion glycolysis in solid tumors C Van de Wiele, V Kruse, P Smeets, M Sathekge, A Maes Eur J Nucl Med Mol Imaging, 2013; 40: 290-301. Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT. Matusiak N, van Waarde A, Bischoff R, Oltenfreiter R, van de Wiele C, Dierckx RA, Elsinga PH. Curr Pharm Des 2013, 19: 4647-4675. Three-phase adaptive dose-painting-by-numbers for head and neck cancer: initial results of the phase I clinical trial. Berwouts D, Olteanu L, Duprez F, Vercauteren T, De Gersem W, De Neve W, Van de Wiele C, Madani I.Radiother Oncol 2013; 107: 310-316. Human biodistribution and dosimetry of 195mPt-cisplatin M Sathekge, J Wagenerer, N Soni, B Marjanovic-Painter, C Zinn, C Van de Wiele, Y D’ASseler, G Perkins, S Smith, J Zeevaart Nuklearmedizin 2013, 52: 222-227. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals M Sathekge, A Maes, M Vorster, Y D’Asseler, C Van de Wiele Nucl Med Communications, 2012, 33: 581-590. Tuberculous lymphadenitis: FDG PET and CT findings in responsive and non-responsive disease M Sathekge, A Maes, Y ‘Asseler, M Kgomo, C Van de Wiele Eur J Nucl Med, 2012, 39: 1184-1190. Reply: 18F-FDG PET/CT as a sensitive and early treatment monitoring tool: will this become the major thrust for its clinical application in infectious and inflammatory conditions. M Sathekge, A Maes, C Van de Wiele J Nucl Med, 2012;53: 165-166. SIRT of liver metastases: physiological and pathophysiological considerations C Van de Wiele, A Maes, E Brugman, Y D’Asseler, B De Spiegeleer, G Mees, K Stellamans Eur J Nucl Med Mol Imaging, 2012; 10: 1646-1655. Tumor perfusion using first pass FDG PET images J Mertens, H Ham, A DeZutter, A Depicker, C Van de Wiele, Smeets P, Goethals I Clin Nucl Med 2012; 37: 166-167. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases S De Bruyne, N VanDamme, K Geboes, W Ceelen, P Smeets, S Laurent, L Ferdinande, J Mertens, C Van de Wiele, R Troisi, M Peeters Br J Cancer, 2012; 106: 1926-1933. Standardized added metabolic activity (SAM), a partial volume independent marker of total lesion glycolysis J Mertens, A Dobbeleir, H Ham, Y D’Asseler, I Goethals, C Van de Wiele Eur J Nucl Med, 2012; 39: 1441-1448. In vitro 18F-FDG uptake: practical considerations K Mertens, G Mees, B Lambert, C Van de Wiele, I Goethals Cancer Biother Radiopharm, 2012; 27: 183-188. 99mTc-tricarbonyl-His-CNA35 as an imaging agent for the detection of tumor vasculature G Mees, R Dierckx, K Mertens, S Vermeire, M Vansteenkiste, C Reutelingsperger, Y D’Asseler, K Peremans, N Van Damme, C Van de Wiele J Nucl Med 2012, 53: 464-471. In vitro metabolic stability of iodinated obestatin peptide B De Spiegeleer, S Vandorpe, V Vergote, E Pauwels, C Van de Wiele, JC Saint-Solis, P Garcia-Solis J Biochemistry, 2012; 33: 272-278. Brainpeps: the blood-brain barrier peptide database S Vandorpe, A Ronselaer, S Stalmans, K Audenaert, C Van de Wiele, C Burvenich, K Peremans, H Hsuchou, G De Tre, B De Spiegeleer Brain Struct Funct Journal, 2012; 217: 687-718. The potential role of quorum-sensing peptides in oncology E Wynendaele, E Pauwels, C Van de Wiele, C Burvenich, B De Spiegeleer Medical Hypotheses, 2012, 78: 814-817. SPECT imaging of the early time course of therapy-induced cell death using 99mTc-(CO)3 His-annexin A5 in a colorectal cancer xenograft model C Vangestel, C Van de Wiele, G Mees, S Staelens, C Reutelingsperger, P Pauwels, N Van Damme, M Peeters Mol Imaging, 2012, 11: 135-147. Multimerization improves targeting of peptide radio-pharmaceuticals G Carlucci, H Ananias, Z Yu, C Van de Wiele, R Dierckx, I de Jong, Ph Elsinga Curr Pharm Des, 2012, 18: 2501-2516. Use of FDG PET to predict response to first line tuberculostatics in HIV-associated tuberculosis M Sathekge, A Maes, M Kgomo, A Stolz, C Van de Wiele J Nucl Med, 2011, 52: 880-885. In vivo imaging of apoptosis : an update C Vangestel, G Mees, R Oltenfreiter, H Boersma, Ph Elsinga, C Reutelingsperger, B De Spiegeleer, M Peeters, C Van de Wiele Mol Imaging, 2011; 10: 340-358. Expression and prognostic value of glucose transporters and hexokinases in tonsil and mobile tongue squamous cell carcinoma Ph Deron, H Vermeersch, G Mees, V Vangestel, P pauwels, C Van de Wiele Histology and Histopathology, 2011; 26: 1165-1172. FDG uptake in primary squamous cell carcinoma of the head and neck. The relationship between overexpression of glucose transporters and hexokinases, tumor proliferation and apoptosis. Ph Deron, C Vangestel, I Goethals, A De Potter, M Peeters, H Vermeersch, C Van de Wiele Nuklearmedizin, 2011; 50: 15-21. Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography. Ph Deron, K Bonte, H Vermeersch, C Van de Wiele Cancer Biother Radiopharm 2011; 26: 331-334. Metabolic correlates of tumour hypoxia in a spontaneous canine mammary gland tumour G Mees, C Vangestel, R Dierckx, S Loomans, N Van Damme, Peremans K, H De Rooster, B Van Goetham, P Pauwels, R Ducatel, C Van de Wiele Research in Veterinary Oncology, 2011; 91: e125-128. Metabolic tumour volume. Prognostic value in locally advanced squamous cell carcinoma of the head and neck Ph Deron, K Mertens, I Goethals, S Rottey, W De Neve, H Vermeersch, C Van de Wiele Nuklearmedizin, 2011; 50: 141-146. Quantitative perfusion scintigraphy or anatomic segment method for estimating pospoperative pulmonary function in resected lung cancer patients: a retrospective analysis T Holvoet, J Van Meerbeeck, C Van de Wiele, B Salhi, E Derom Lung Cancer, 2011, 74: 212-218 99mTc-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14), a targeted imaging agent with microspect in a PC-3 prostate cancer xenograft model. H Ananias, Z Yu, RA Dierckx, C Van de Wiele, W Helfrich, F Wang, Y Yan, X Chen, I De Jong, Ph Elsinga Mol Pharm 2011, 8: 1165-1173. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. I Madani, F Duprez, T Boterberg, C Van de Wiele, K Bonte, P Deron, W dGersem, M Coghe, De Neve W Radiother Oncol 2011, 101: 351-355. 99mTc-(CO)3 His-Annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. C Vangestel, C Van de Wiele, N Van Damme, S Staelens, P Pauwels, C Reutelingsperger, M Peeters J Nucl Med 2011, 52: 1786-1794. FDG uptake by lymph nodes of HIV patients is inversely related to CD4 cell count M Sathekge, A Maes, M Kgomo, C Van de Wiele Nucl Med Commun, 2010, 31: 137-140. Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy M Sathekge, A Maes, M Kgomo, A Stolz, A Alfred, C Van de Wiele Nucl Med Commun, 2010, Feb, 31: 311-314. Impact of FDG PET imaging on the management of TBC treatment: a pilot study M Sathekge, A Maes, M Kgomo, A Stolz, H Pottel, C Van de Wiele Nuklearmedizin 2010;49: 35-40. Dual time point PET/CT for differentiating benign from malignant solitary pulmonary nodules: a prospective study M Sathekge, A Maes, M Kgomo, H Pottel, C Van de Wiele S Afr J Med, 2010, 100; 598-601. Scapular osteomyelitis as a rare complication of staphylococcus aureus endocarditis: bone scintigraphy findings J Mertens, V Van Gaever, H Ham, C Van de Wiele Clin Nucl Med 2010, 35: 595-597. FDG uptake in lymph nodes of HIV+ and tuberculosis patients: implications for cancer staging M Sathekge, A Maes, M Kgomo, H Pottel, A Stolz, C Van de Wiele Quart J Nucl Med, 2010, 54: 698-703. Radioembolization in hepatocellular carcinoma C Van de Wiele CDDP, 2010; 7: 247-252. FDG PET in children: do we have enough counts A Dobbeleir, H Ham, I Goethals, Y D’Asseler, C Van de Wiele Nucl Med Commun, 2010; 31: 191-194. CA-IX expression correlates with FDG uptake by primary NSCLC G Mees, C Van Gestel, R Dierckx, P Pauwels, J Van Meerbeeck, C Van de Wiele Cancer Biother Radiopharm, 2010; 25: 149-154. A simple test to determine the quality of your clinical PET images A Dobbeleir, H Ham, I Goethalsd, J Keppens, Y D’Asseler, C Van de Wiele Ann Nucl Med 2010; 24: 751-777 Membrane type 1 Matrix Metalloproteinase detection in tumors, using the iodinated endogenous  [123I]-Tissue inhibitor 2 of metalloproteinases as imaging agent M Van Steenkiste, C Van de Wiele, F De Vos Cancer Biotherapy and Radiopharmaceuticals, 2010, 25: 511-520 Measurement of porto-systemic shunting in mice by novel three-dimensional micro-single photon emission computed tomography imaging enabling longitudinal follow-up C Van Steenkiste, S Staelens, C Deleye, F De Vos, S Vandenberghe, A Geerts, C Van de Wiele, M De Vos, H Van Vlierverghe, I Colle Liver Int, 2010, 30: 1211-1220 In vitro and in vivo evaluation of 99mTc-labeled tricarbonyl His- annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells C Vangestel, M Peeters, R Oltenfreiter, S Staelens, Y D’Asseler, M Van Steenkiste, J Philippé , D Kusters, C Reutelingsperger, N Van Damme , C Van de Wiele J Nucl Med Biol, 2010, 37: 965-975 Positron emission tomography in patients suffering from HIV M Sathekge, A Maes, C Van de Wiele Eur J Nucl Med, 2009; 36: 1176-1184. RIT of NHL: the next step A Otte, C Van de Wiele, R Dierckx Nuc Med Commun 2009; 30: 5-15. Radiolabelled resin microspheres for the treatment of primary and secondary malignant liver tumors
C. Van de Wiele, L. Defreyne, A. Maes, M. Peeters, B. Lambert Quart J Nucl Med 2009; 53: 317-324. FDG-PET for monitoring response to local and locoregional therapy in HCC and livermetastases R. Dierckx, A. Maes, M Peeters, C. Van de Wiele Quart J Nucl Med 2009; 53: 336-342. Selective internal radionuclide therapy of HCC and livermetastases: a locoregional or worldwide therapy? C. Van de Wiele Quart J Nucl Med 2009; 53: 302-304. Expression of hexokinases and glucose transporters in treated and untreated esophageal adenocarcinoma P Phonteyne, P Pauwels, V Casneuf, N Vandamme, M Peeters, R Dierckx, C Van de Wiele Histology and histopathology, 2009; 24: 971-977. Molecular imaging of hypoxia with radiolabeled agents G Mees, C Vangestel, R Dierckx, C Van de Wiele Eur J Nucl Med Molecular Imaging, 2009; 36: 1674-1686. Combined effect of EPO and radiotherapy on the expression of endogenous markers of tumor metabolism and metastasis G Mees, Ph Phonteyne, W Ceelen, T Boterberg, P Pauwels, C Vangestel, N Vandamme, M Peeters, R Dierckx, C Van de Wiele Cancer Biother Radiopharm, 2009; 24: 565-572. Influence of chemotherapy on the biodistribution of 99mTc-HYNIC Annexin V in humans S Rottey, B Van den Bossche, G Slegers, S Van Belle, C Van de Wiele Quart J Nucl Med, 2009, 53: 127-132 The immune system and cancer D Loose, C Van de Wiele Cancer Biother and Radiopharm, 2009, 24: 369-376 Gallium citrate scintigraphy to assess metastatic spread in a dog with an oral melanoma T Liuti , J de Vos , T Bosman , C Van de Wiele , G Grinwis, H van Bree, K Peremans J Small Anim Pract. 2009, 50: 31-34 Forcing cancer cells to commit suicide C Van Gestel, C Van de Wiele, G Mees, M Peeters Cancer Biother Radiopharm, 2009, 24: 395-407 Glomerular filtration rate is a confounder for the determination of soluble mesothelin in serum Hollevoet K, Bernard D, De Geeter F, Walgraeve N, Van den Eeckhaut A, Vanholder R, Van de Wiele C, Stove V, van Meerbeeck J, Delanghe J Clinical Chemistry, 2009, 55: 1431-1433 Development of peptide receptor binding assays: methods to avoid false negatives V Vergote, S Van Dorpe, M Verbeken, C Burvenich, C Van de Wiele, W Banks, B De Spiegeleer Eur J Nucl Med, 2009, 158: 97-102 Quality specifications for peptide drugs: a regulatory-pharmaceutical approach V Vergote, C Burvenich, C Van de Wiele , B De Spiegeleer J Peptide Science, 2009, 15: 697-710 Post-stress left ventricular ejection fraction is an independent predictor of major cardiac events in patients with coronary artery disease and impaired left ventricular function O De Winter, N Van de Veire, P De Bondt, C Van de Wiele, M De Buyzere, G De Backer, T Gillebert, R Dierckx, J De Sutter Quarterly J Nucl Med, 2008: 52: 296-304. Growth factor/ peptide receptor imaging for the development of targeted therapy in oncology C Van de Wiele, Boersma H, Dierckx R, De Spiegeleer B, Elsinga Ph Current Pharmaceutical Design, 2008; 14: 3340-3347. FDG uptake by the bone marrow in NSCLC patients is related to TGF- but not to VEGF or G-CSF C Van de Wiele, F VandeVyver, C Debruyne, J Philippé, J van Meerbeeck Eur J Nucl Med, 2008; 35: 519-522. FDG PET, a marker of hypoxia? RA. Dierckx, C Van de Wiele Eur J Nucl Med, 2008; 35: 1544-1549. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. V Casneuf, Ph Fonteyne, N Van Damme, P Demetter, P Pauwels, B de Hemptinne, M De Vos, C Van de Wiele, M Peeters Cancer Investigations, 2008; 26: 852-859. FDG uptake of the primary tumor in untreated primary squamos cell carcinoma of the head and neck is related to WBC count and to FDG uptake by the bone marrow F Cicone, Ph Deron, H Vermeersch, A Signore, F Scopinaro, C Van de Wiele Nucl Med Commun, 2008; 29: 431-435. 123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck D Loose, A Signore, L Staelens, K Vanden Bulcke, H Vermeersch, R Dierckx, E Bonanno, C Van de Wiele Eur J Nucl Med, 2008; 35: 281-286 Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous cell carcinoma of the head and neck D Loose, A Signore, E Bonanno, H Vermeersch, R Dierckx, Ph Deron, C Van de Wiele Cancer Biother Radiopharm, 2008, 23: 25-33. Gastrin releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry C Van de Wiele, Ph Phonteyne, P Pauwels, R Vandenbroecke, V Cocquyt, R Dierckx J Nucl Med, 2008, 49: 260-264. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals Ananias H, de Jong I, Dierckx R, Van de Wiele C, Elsinga Ph Current Pharmaceutical Design, 2008, 14; 3033-3047 Radiolabelled chemotherapeutics S Rottey, A Signore, C Van de Wiele Quart J Nucl Med, 2007; 51: 139-151. Differences of cortical 5-HT2a receptor binding with SPECT in subtypes of anorexia nervosa I Goethals, M Vervaet, K Audenaert, F Jacobs, C Van de Wiele, H ham, RA Diercxk, C Van Heeringen J Psychiatr Res, 2007; 41: 455-458 IL-2 imaging in patients suffering from metastatic renal cell carcinoma V Renard, L Staelens, A Signore, S Van Belle, R Diercxk, C Van de Wiele Quart J Nucl Med, 2007; 51: 352-356 99mTc-HYNIC Annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy S Rottey, Loose D, Vakaet L, Lahorte C, Vermeersch H, Van Belle S, Van de Wiele C Quarterly J Nucl Med, 2007, 51: 182-188 Fasting blood glucose levels are related to exercise capacity in coronary artery disease patients Van de Veire N, De Winter O, Giri M, De Buyzere M, Van de Wiele C, De Sutter J Am Heart J, 2006, 152: 486-492. 123I-labelled Interleukin-12, a new radiopharmaceutical for imaging th-1 mediated chronic inflammation: in vitro and animal studies A Annovazzi, B Cornelissen, G Slegers, C D’Alessandria, E Bonanno, C Van de Wiele, F Scopinaro, A Signore Cancer Biother Radiopharm 2006; 33: 474-482. 188Re-HDD/Lipiodol therapy for hepatocellular carcinoma: an activity escalation study B Lambert, K Bacher, L Defreyne, H Van Vlierberghe, JM Jeong, RF Wang, JP Van Meerbeeck, P Smeets, R Troisi, H Thierens, F De Vos, C Van deWiele Eur J Nucl Med, 2006; 33: 344-352. Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for HCC B Lambert, L De Ridder, F De Vos, G Slegers, V De Gelder, C Van de Wiele, H Thierens Can J Physiol Pharmacol, 2006; 84: 1021-1028. Nuclear medicine imaging in veterinary oncology Peremans K, Van Bree P, Audenaert K, Van de Wiele C Tijdschrift voor Diergeneeskunde, 2006 Early prediction of the efficacy of endocrine therapy in advanced breast cancer patients using 99mTc-Depreotide scintigraphy Vanden Bossche B, Van Belle S, De Winter F, Signore A, Van de Wiele C J Nucl Med, 2006, 47: 6-13 Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis Coppieters K, Dreier T, Silence K, Haard HD, Lauwereys M, Casteeks P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers P Arthritis Rheumatism, 2006: 1856-1866 Synthesis of 99mTc-HYNIC-Interleukin-12, a new specific radiopharmaceutical for imaging T-lymphocytes A Annovazzi, C D’Alessandria, E Bonanno, SJ Mather, B Cornelissen, C Van de Wiele, RA Dierckx, M Mattei, G Palmieri, F Scopinaro, A Signore Eur J Nucl Med, 2006, 33: 474-482 Valine-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents. Oltenfreiter R, Staelens L, Kersemans V, Cornelissen B, Frankene F, Foidart J, Van de Wiele C, Slegers G Applied Radiation and isotopes, 2006, 64: 677-685 Imaging probes targeting matrix metalloproteinases Van de Wiele C, Oltenfreiter R Cancer Biother Radiopharm, 2006; 21: 409-417 Sequential 99mTc-HYNIC Annexin-V imaging for predicting response to therapy S Rotteye, C Lahorte, S Van Belle, C Van de Wiele J Nucl Med, 2006, 47: 1813-1818 Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for HCC B Lambert, L De Ridder, F De Vos, G Slegers, V De Gelder, C Van de Wiele, H Thierens Can J Physiol Pharmacol, 2006, 84: 1021-1028 Optimized tracer-dependent dosage cards to obtain weight-dependent effective doses F Jacobs, H Ham, C Van de Wiele , R Dierckx , H Thierens Eur J Nucl Med, 2005, 32: 581-588. Incremental prognostic value of combined perfusion and function assessment during myocardial gated SPECT in patients aged 75 years or older De Winter O, Velghe A, Van de Veire N, De Bondt P, De Buyzere M, Van de Wiele C, De Backer G, Gillebert TC, Dierckx RA, De Sutter J J Nucl Cardiol 2005; 12: 662-670. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial B Lambert, K Bacher, L Defreyne, F Gemmel, H Van Vlierberghe, JM Jeong, RA Dierckx, C Van de Wiele, H Thierens, F De Vos F J Nucl Med, 2005; 46: 60-66. Radiolabelled lipiodol therapy for HCC in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome B Lambert, M Praet, P Van Langenhove, R Troisi, B de Hemptinne, F Gemmel, H Van Vlierberghe, C Van de Wiele Cancer Biother Radiopharm, 2005; 20: 209-214. Radiopharmaceuticals for treatment of HCC B Lambert, C Van de Wiele Eur J Nucl Med, 2005; 32: 980-989. 188Re-HDD/Lipiodol for Treatment of Hepatocellular Carcinoma: A Feasibility Study in Patients with Advanced Cirrhosis Lambert B, Bacher K, De Keukeleire K, Smeets P, Colle I, Jeong JM, Thierens H, Van de Wiele C J Nucl Med, 2005; 46: 1326-1332. Small animal imaging by means of conventional planar and pinhole SPECT gamma camera imaging K Peremans, B Cornelissen, B Van den Bossche, K Audenaert, C Van de Wiele Vet Radiol and Ultrasound, 2005, 46: 162-170 A forum for IRIST C Van de Wiele, A Signore Quarterly Journal of Nuclear medicine, 2005, 49: 299-300 Absence of Tc-99m HIG joint uptake in a patient suffering from SLE presenting with polyarticular joint complaints F Jacobs, RA Dierckx, E Vrancken, F De Vos, C Van de Wiele Clin Nucl Med, 2005, 30: 124-125 Differences of cortical 5-HT2a receptor binding with SPECT in subtypes of anorexia nervosa I Goethals, M Vervaet, K Audenaert, F Jacobs, C Van de Wiele, H Ham, RA Dierckx, C Van Heeringen J Psychiatr Res, 2005, may, epub ahead of print Blunted prefrontal perfusion response in depressed patients using SPECT and the TOL task I Goethals, K Audenaert, F Jacobs, C Van de Wiele, H Pyck, A Vandierendonck, C Van Heeringen, R Dierckx Psychiatry Res, 2005, 139: 31-40 Radiolabelled lipiodol therapy for HCC in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome
B Lambert, M Praet, P Van Langenhove, R Troisi, B de Hemptinne, F Gemmel, H Van Vlierberghe,
C Van de Wiele Cancer Biother Radiopharm, 2005 ; 20: 209-214 In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy. B Cornelissen, C Lahorte, V Kersemans, G Capriotti, E Bonano, A Signore, C Van de Wiele, R Dierckx, G Slegers. Nucl Med Biol, 2005, 32: 233-239 In vivo evaluation of [(123)I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D(4) receptor ligand for SPECT studies. Staelens L, Oltenfreiter R, Blanckaert P, Kersemans V, Vandenbulcke K, Van De Wiele C, Slegers G. Nucl Med Biol, 2005;32:293-299. Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor Cornelissen B, Kersemans V, Burvenich I, Oltenfreiter R, Vanderheyden JL, Boerman O, Van de Wiele C, Slegers G Nucl Med Commun, 2005; 26: 147-153. Tryptophane-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumour imaging agents Oltenfreiter R, Staelens L, Vervoort L, Kersemans V, Frankenne F, Noël A, Van de Wiele C, Slegers G Cancer Biother Radiopharm, 2005; 20: 659-641 In Reply to: Use of radiolabeled bombesin in humans (Scopinaro et al. 2005; 23:3170-3171) B Van den Bossche, C Van de Wiele J Clin Oncol, 2005; 23: 1371. Day-to day variability of global and regional left ventricular functional measurements by 99mTechnetiu tetrofosmin determined by Quantitative Gated SPET in patients with heart failure due to CAD. O De Winter, P De Bondt, C Van De Wiele, G De Backer, Rudi A. Dierckx, J De Sutter J Nucl cardiol, 2004, 11: 47-52. Renal toxicity after internal radionuclide therapy B Lambert, M Cybulla, SM Weiner, C Van de Wiele, H Ham, RA Dierckx, A Otte Rad Res, 2004; 161: 607-611. 99mTc ciprofloxacin planar and tomographic imaging for the diagnosis of infection in the postoperative spine: experience in 48 patients F De Winter, F Gemmel, K Van Laere, O De Winter, B Poffijn, RA Dierckx, C Van de Wiele Eur J Nucl Med, 2004; 31: 233-239. Molecular imaging in oncology by means of nuclear medicine: facts or fiction C Van de Wiele Eur J Nucl Med, 2004; 2: 151-154. Receptor imaging by means of nuclear medicine: current status B Van den Bossche, C Van de Wiele J Clin Oncol, 2004; 22: 3593-3607. Cell death detecting radioligands: current state of the art and future perspectives C Lahorte, JL vanderheyden, N Steinmetz, C Van de Wiele, RA Dierckx, G Slegers Eur J Nucl Med, 2004, 31: 887-919. New strategies in polypeptide and antibody synthesis N Mertens, F De Vos, J Leoen, E Van Deynse, A Willems, S Schoonooghe, S De Koker, I Burvenich, D Vlieghe, J Grooten, A Kelly, C Van de Wiele Cancer Biother Radiopharm, 2004, 1: 99-110 The proceedings of the 16th IRIST (International Research Group on Immunoscintigraphy and Immunotherapy) Congress 8-10 May 2003, Capri, Italy A Signore A, C Van de Wiele, M De Jong M Cancer Biother Radiopharm, 2004, 1: 55-56 Radioiodine recombinant TSH: A novel radiopharmaceutical for thyroid cancer metastases detection F Corsetti, M Chianelli, B Cornelissen, C Van de Wiele, C D’Allessandria, G Slegers, S Mather, U Di Mario, S Filetti, F Scopinaro, A Signore Cancer Biother Radiopharm 2004; 1: 57-64. Radiolabelled annexin-V for monitoring treatment response in oncology C Van de Wiele, H Vermeersch, D Loose, A Signore, RA Dierckx Cancer Biother Radiopharm, 2004, 2: 205-210. The prefrontal cortex: insights from functional neuroimaging using cognitive activation tasks I Goethals, K Audenaert, C Van de Wiele, RA Dierckx Eur J Nucl Med, 2004, 3; 408-416 99mTc-HYNIC Annexin-V C Van de Wiele IDRUGS, 2004, 7; 264-269 123I-labelled Interleukin-12, a new radiopharmaceutical for imaging th-1 mediated chronic inflammation: in vitro and animal studies A Annovazzi, B Cornelissen, G Slegers, C D’Alessandria, E Bonanno, C Van de Wiele, F Scopinaro, A Signore Cancer Biother Radiopharm 2004, in press Intra-, Inter- and day-to-day reproducibility of quantitative 99mTc-HYNIC Annexin imaging in head and neck carcinoma H Vermeersch, H Ham,C Lahorte, Loose D, G Slegers, RA Dierckx, C Van de Wiele Cancer Biother Radiopharm, 2004, 2: 205-210. 99mTc-HYNIC Annexin-V imaging of primary head and neck carcinoma, a comparison with CT H Vermeersch, D Loose, C lahorte, K Mervillie, RA Dierckx, N Steinmetz, JL Vanderheyden, C Cuvelier, G Slegers, C Van de Wiele Nucl Med Commun, 2004, 3: 259-264 Radiolabelling, biodistribution and dosimetry of 123I-Mab 14C5: a new monoclonal antibody for radioimmunodetection of tumor growth and metastasis in vivo C lahorte, Bacher K, Burvenich I, Coene E, Cuvelier C, De Potter C, Thierens H, C Van de Wiele, RA Dierckx, Slegers G J Nucl Med, 2004, 45: 1065-1073 Oestrogen mediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc Depreotide B Van Den Bossche, E D’Haeninck, F De Vos, RA Dierckx, M Bracke, C Van de Wiele Eur J Nucl Med, 2004, 31: 1022-1030 99mTc depreotide scan compared with 99mTc MDP bone scintigraphy for the detection of bone metastases and prediction of hormonal treatment response in breast cancer B Van Den Bossche, E D’Haeninck, F De Winter, S Van Belle, RA Dierckx , C Van de Wiele Nucl Med Commun, 2004, 25: 787-792 Relationship between Fas-L expression, MMP-9 expression, microvesseldensity and quantitative 99mTc-HYNIC Annexin imaging in squamous cell carcinoma of the head and neck H Vermeersch, K Mervillie, C Lahorte, D Loose, N Steinmetz, G Slegers, RA Dierckx , C Van de Wiele Eur J Nucl Med, 2004, 31: 1016-1021 The 17th IRIST MEETING REPORT C Van de Wiele, A Signore Cancer Biotherapy and Radiopharmaceuticals, 2004; 19: 719-722 Biodistribution and dosimetry of 99mTc Depreotide in patients B Van den Bossche, E D’Haeninck, K Bacher, H Thierens, S Van Belle, R Dierckx, C Van de Wiele Cancer Biother Radiopharm 2004, 2004; 19: 779-787 Comparison of cortical 5-HT2A receptor binding in bulimia patients and healthy volunteers. I Goethals, M Vervaet, K Audenaert, C Van de Wiele, H Ham, M Vandecapelle, G Slegers, C van Heeringen , RA Dierckx. Am J Psychiatry, 2004, 10: 1916-1918 Neuroactivation using SPECT and the stroop coloured word test in patients with diffuse brain injury I Goethals, K Audenaert, F Jacobs, E Lannoo, C Van de Wiele, H Ham, A Otte, K Oostra, R Dierckx J Neurotrauma, 2004, 21; 1059-1069 Application of a neuropsychological activation probe with SPECT: the tower of London task in healthy volunteers I Goethals, F Jacobs, K Audenaert, C Van de Wiele, P Hanneke, A Vandierendonck, C Van Heeringen, RA Dierckx Nucl Med Commun , 2004, 2; 177-182. In vitro and in vivo suitability of 123I-hEGF for monitoring farnesyl transferase inhibitor therapy B Cornelissen, T Thonissen, V Kerseman, C Van de Wiele, F Jacobs, RA Dierckx, G Slegers Nucl Med Biol, 2004, 31: 379-389 Registration accuracy of Gd-153 transmission images of the brain F Jacobs, M Koole, I Goethals, C Van de Wiele, H Ham, Dierckx RA Eur J Nucl Med, 2004, 31; 11: 1495-1499 Advances and prospects in radioimmunoimaging C Van de Wiele, H Revets, N Mertens Quarterly Journal of Nuclear Medicine, 2004, 48: 317-325. The choice of radiopharmaceutical to image breast cancer G Capriotti, C Van de Wiele, F Scopinaro, A Signore World J Nucl Med, 2004; 3: 258-260 Nuclear medicine in the prediction and detection of radiation associated normal tissue damage of kidney, brain, bone marrow and salivary glands. Goethals I, Dierckx R, De Meerleer G, Gemmel F, De Neve W, Van De Wiele C. Nucl Med Commun. 2003 Aug;24(8):845-52. Validation of planar and tomographic radionuclide ventriculography by a dynamic ventricular phantom P De Bondt, S Vandenberghe, S De Mey, P Segers, O De Winter, J De Sutter, C Van de Wiele, P Verdonck, RA Dierckx Nucl Med Comun, 2003; (24)7: 771-777. Tomographic radionuclide ventriculography measurements tested with a biventricular dynamic physical phantom P De Bondt, K Nichols, S Vandenberghe, P Segers , O De Winter, J De Sutter, C Van de Wiele, P Verdonck, S Bergmann, RA Dierckx. J Nucl Med, 2003: 44(6): 967-972. Place of ultrasonography in the assessment of renal function in the old old N Van den Noortgate, A Velghe, M Petrovic, C Van de Wiele, N lameire, D Voet, M Afschrift J Nephrol, 2003; 16: 658-662. FDG PET for the diagnosis of infection in the postoperative spine F De Winter, F Gemmel, C Van de Wiele, B Poffijn, D Uyttendaele, RA Dierckx Spine, 2003; 28: 1314-1319. Nuclear medicine imaging to predict response to radiotherapy: past and future C Van de Wiele, C Lahorte,W Oyen, O Boerman, I Goethals, RA Dierckx IJROBP, 2003; 1: 5-15. Novel PET and SPECT radiopharmaceuticals for imaging breast tumor biology C Van de Wiele, A Signore, R Waterhouse, RA Dierckx, F Scopinaro Nucl Instrum Meth A, 2003; A497: 30-38. Is Flumazenil PET useful for detecting epileptic foci : a review I Goethals, C Van de Wiele, P Boon, RA Dierckx Eur J Nucl Med, 2003; 30: 325-328. Fluorine-18 2-deoxy-D-glucose positron emission tomography in neoplastic disorders of the gastrointestinal tract A Annovazzi, M Peeters, A Signore, RA Dierckx, C Van de Wiele Gastroenterology, 2003; 125: 1235-1245. Nuclear Medicine Imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers Vermeersch H, Loose D, Ham H, Otte AS, Van de Wiele C Eur J Nucl Med, 2003, 30: 1689-1700 False-negative Tc-99m MIBI scintigraphy in a patient with histopathological-proven recurrent high-grade oligodendroglioma I Goethals, O De Winter, A Annovazzi, A Signore, RA Dierckx, C Van de Wiele Clin Nucl Med, 2003, 28(4): 299-301 Biodistribution and dosimetry of 123I-rh-annexin V in mice and humans C Lahorte, C Van de Wiele, K Bacher, B Van den Bossche, H Thierens, G Slegers, RA Dierckx Nucl Med Commun, 2003, 24: 871-880 Non-Invasive quantitative tumour apoptosis imaging by means of 99mTc-HYNIC Annexin single photon emission computerized tomography C Van de Wiele, C Lahorte, H Vermeersch, Loose D, Mervillie C, Cuvelier C, Slegers G, Dierckx RA J Clin Oncol, 2003, 21: 3483-3487 99mTc Sestamibi and 99mTc Tetrofosmin scintigraphy to predict resistance to chemotherapy: a critical review C Van de Wiele, S Rottey, I Goethals, J Buscombe, S van Belle, F De Vos, RA Diercxk Nucl Med Commun 2003, 24: 945-950 The role of nuclear medicine in the prediction and detection of radiation-associated extrathoracic damage I Goethals , RA Dierckx, G De Meerleer, F Gemmel, W De Neve , C Van de Wiele Nucl Med Commun, 2003, 24: 845-852 The exceptional brain of Maurice Ravel A Otte, P De Bondt, C Van de Wiele, K Audenaert, RA Dierckx Med Sci Monitor 2003; 9(6): RA113-138 Toward clinical application of neuropsychological activation probes with SPECT: a spatial working memory task I Goethals, K Audenaert, F Jacobs, C Van de Wiele, C Van Heeringen, RA Dierckx J Nucl Med, 2002,43: 1426-1431 The role of whole blood viscosity in premature coronary artery disease in women De Backer TL, De Buyzere M, Segers P, carlier S, De Sutter J, Van de Wiele C, De Backer G Atherosclerosis, 2002, 165(2): 367-373 The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage: a review I Goethals, O De Winter, J De Sutter, P De Bondt, RA Dierckx, C Van de Wiele Ann Oncol, 2002, 13: 1331-1339. Peptide receptor imaging: Advances in the diagnosis of pulmonary diseases C Van de Wiele, A. Signore, RA Dierckx Am J Resp Med; 2002, 1: 177-183. Discordant findings between 99mTc HMPAO mixed white blood cells and 99mTc Leucoscan in a patient suffering from aspergillosis of the lung I Goethals, O De Winter, L D’Ignazio, A Signore, RA Dierckx, C Van de Wiele Clin Nucl Med, 2002; 27: 596-596. Is there a role for nuclear medicine imaging in routine assessment of infectious brain pathology I Goethals, RA Dierckx, K Van Laere, A Signore, C Van de Wiele Nucl Med Commun, 2002; 23: 819-826. Nuclear medicine imaging for prediction or early assessment of response to chemotherapy in patients suffering from breast carcinoma C. Van de Wiele, RA. Dierckx, F. Scopinaro, R. Waterhouse, A. Annovazzi, A. Kolindou, A. Signore Breast Cancer Res Treat, 2002; 72: 275-282. Fluorodeoxyglucose triple headed coincidence detection imaging in oncology : preliminary results and comparison with dedicated PET F De Winter, C Van de Wiele, S Vandenberghe, B Vandenbossche, Y D’Asseler, D Huglo, RA Dierckx Med Science Monitor, 2002; 8: MT89-94 High-dose 67Ga versus FDG PET for restaging of lymphoma patients B Van Den Bossche, B Lambert, F De Winter, RA Dierckx, L Noens, C Van de Wiele Nucl Med Commun, 2002; 23: 1079-1083 Assessment of cancer associated biomarkers by positron emission tomography: advances and challenges TL Collier, R lecomte, T McCarthy, S Meikle, TJ Ruth, F Scopinaro, A Signore, H VanBrocklin, C Van de Wiele, RN waterhouse Dis Markers, 2002; 18: 211-247 Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging C Van de Wiele, R Oltenfreiter, O De Winter, A Signore, G Slegers, RA Dierckx Eur J Nucl Med, 2002, 29: 699-709 Leakage assessment in adjustable laparoscopic gastric banding: radiography versus 99mTc pertechnetate scintigraphy B Vandenbossche, RA Dierckx, G Villeirs, J Pattyn, C Van de Wiele Eur J Nucl Med, 2002, 29: 1128-1131 Brain hypoperfusion in early Alzheimer disease: where to look I Goethals, C Van de Wiele, D Slosman, RA Dierckx Eur J Nucl Med, 2002, 29: 975-978 Biodistribution studies and displacement studies of 123I-5-I-R91150 in the normal dog K Peremans, K Audenaert, F Jacobs, F Dumont, F De Vos, C Van de Wiele, M Vandecapelle, H van Bree F Verschooten, G Slegers, J Mertens, RA Dierckx. Nucl Med Commun, 2002, 23: 1019-1027. Radiolabelled pyrimidines and derivatives for measuring cellular proliferation, an update C Van de Wiele, P De Bondt, M Peeters, RA Dierckx Nucl Med Commun, 2002, 23: 925-931 Synthesis and in vitro evaluation of 123I-labelled human recombinant annexin V C Lahorte, G Slegers, J Philippé, C Van de Wiele, RA Dierckx Biomol Eng 2001, 17: 51-53. Technetium-99m-labelled HL 91 versus CT and biopsy for the visualisation of tumor recurrence of squamous head and neck carcinoma C Van de Wiele, J Versijpt, RA Dierckx, M Moerman, M Lemmerling, Y D’Asseler, H Vermeersch Nucl Med Com 2001, 22(3): 269-275 Is there a role for agonist gastrin releasing peptide receptor radioligands in tumour imaging? C Van de Wiele, F Dumont, S Van Belle, G Slegers, SH Peers, RA Dierckx Nucl Med Comm 2001, 22(1): 5-15 High performance liquid chromatographic determination of (iodine-123)-iodomethyl-N,N-diethyltamoxifen derivative in human plasma F De Vos, C Van de Wiele , M Vandecapelle , G Slegers, RA Dierckx Nucl Med Biology, 2001, 28(3): 335-338 Dopaminergic neurotransmission in psychiatry: should selection of patients be based on DSM or ICD criteria? I Goethals, K Audenaert, K Van Laere, C Van de Wiele, RA Dierckx Eur J Nucl Med, 2001, 28; 785-788 Dopamine receptor imaging in alcohol dependency: should personality traits be taken into account I Goethals, C Van de Wiele, K Audenaert Eur J Nucl Med; 2001, 28: 1585-1588 Iodine-labelled tamoxifen uptake in primary human breast carcinoma C Van de Wiele, V Cocquyt, R Vandenbroecke, F De Vos, S. Van Belle, G Slegers, RA Dierckx. J Nucl Med, 2001, 42: 1818-1820 Biodistribution and dosimetry of 99mTc RP527, a gastrin releasing peptide agonist for the visualisation of GRP-receptor expressing malignancies C Van de Wiele, F Dumont, RA Dierckx, SH Peers, JR Thornback, G Slegers, H Thierens J Nucl Med; 2001, 42: 1722-1727 Fibrinogen and C-reactive protein on admission as markers of final infarct size after primary angioplasty for acute myocardial infarction J De Sutter, M De Buyzere, P Gheeraert, C Van de Wiele, J Voet, M De Pauw, RA Dierckx, G De Backer, Y Taeymans Atherosclerosis 2001, 157(1): 189-196. Age- and gender-specific differences in left ventricular cardiac function and volumes determined by gated SPECT P De Bondt, C Van de Wiele, J De Sutter, F De Winter, G De Backer, RA Dierckx Eur J Nucl Med, 2001, 38(5): 620-624. Aseptic loosening of a knee prosthesis as imaged on FDG-PET F De Winter, C Van de Wiele, D De Clercq, D Vogelaers, P De Bondt, RA Dierckx Clin Nucl Med 2001, 25: 923-923. Dual head coincidence F-18 FDG imaging using 19 mm Nal (Tl) crystals for the diagnosis of chronic orthopedic infections: a feasibility study F De Winter, C Van de Wiele, S Vandenberghe, P De Bondt, D De Clercq, Y D’Asseler, RA Dierckx J Comput Assist Tomo 2001; 25(2): 184-189. F-18 Flurorodeoxyglucose positron emission tomography: a highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections F De Winter, C Van de Wiele, D Vogelaers, K De Smet, R Verdonk, RA Dierckx J Bone Joint Surg Am, 2001; 83: 651-660. Biodistribution and dosimetry of 99mTc-ciprofloxacin, a promising agent for the diagnosis of bacterial infection F De Winter, C Van de Wiele, F Dumont, J Van Durme, K Solanki, K Britton, G Slegers, RA Dierckx, H Thierens Eur J Nucl Med, 2001; 28: 570-574. Receptor imaging in breast carcinoma: future prospects C Van de Wiele, S Van Belle, G Slegers, RA Dierckx Eur J Nucl Med 2001, 28; 675-679. Imaging tumour hypoxia : where are we? C. Van de Wiele, A. Signore, F. Scopinaro, R. Waterhouse, RA. Dierckx Nucl Med Commun, 2001; 22: 945-947. Peptide radiopharmaceuticals for diagnosis and therapy A Signore, A Annovazzi, M Chianelli, L D’Ignazio, C Van de Wiele, R Waterhouse, F Scopinaro. Eur J Nucl Med, 2001; 28: 1555-1565. Synthesis and in vitro stability of 123-I-labelled annexin V : a potential agent for SPECT imaging of apoptotic cells C Lahorte, F Dumont, G Slegers, C Van de Wiele, RA Dierckx, J Philippé J labelled compd rad 2000; 43: 739-751 PACS and multimodality in medical imaging Y D’Asseler, M Koole, K Van Laere, S Vandenberghe, L Bouwens, R Van de Walle, C Van de Wiele, I Lemahieu, RA Dierckx Technology and Health Care 2000; 8: 35-42 Cardiac fluorine-18 fluorodeoxyglucose imaging using a dual headed gamma camera with coincidence detection: a clinical pilot study J De Sutter, F De Winter, C Van de Wiele, P De Bondt, Y D’Asseler, RA Dierckx Eur J Nucl Med 2000; 27: 676-685. Infarct size and recurrences of ventricular arrythmias after defibrillator implantation J De Sutter, R Tavernier, C Van de Wiele, H Kazmierczak, RA Dierckx, L Jordaens Eur J Nucl Med 2000; 27: 807-815. Automatic quantification of defect size using normal templates: a comparative clinical study of three commercially available algorithms. J De Sutter, C Van de Wiele, Y D’Asseler, P De Bondt, G De Backer, P Rigo, RA Dierckx Eur J Nucl Med 2000; 27: 1827-1834. Prevalence of potential candidates for biventricular pacing among patients with known coronary artery disease: a prospective registry from a single center J De Sutter, P De Bondt, C Van de Wiele, W Fonteyne, RA Dierckx, D Clement, R Tavernier PACE 2000; 23: 1718-1721. 55Co-EDTA for renal imaging using positron emission tomography (PET); a feasibility study P Goethals, A Volckaert, C Van de Wiele, RA Dierckx, N Lameire Nucl Med Biol 2000; 27: 77-81. 57Co-EDTA renal imaging in rats C Van de Wiele, P Goethals, A Volkaert, F De Winter, H Thierens, RA Dierckx Nucl Med Comm 2000; 21: 313-316. 99mTc-MDP uptake in herniated stomach tissue C De Sadeleer, C Van de Wiele, F De Winter, P De Bondt, RA Dierckx Clin Nucl Med 2000; 25: 386-387. The usefulness of HIG-scan for the detection of spinal inflammation in ankylosing spondylitis K De Vlam, C Van de Wiele, H Mielants, RA Dierckx, EM Veys Clin Exp Rheumatol 2000; 18: 379-382. Imaging of giant cell arteritis: evidence of splenic involvement using FDG positron emission tomography F De Winter, M Petrovic, C Van de Wiele, D Vogelaers, M Afschrift, RA Dierckx Clin Nucl Med 2000; 25: 633-634. Radiolabeled estradiol derivates to predict response to hormonal treatment in breast cancer: a review C Van de Wiele, F De Vos, G Slegers, S Van Belle, RA Dierckx Eur J Nucl Med 2000; 27: 1421-1433. Variability study of a non-invasive approach to absolute quantification of cerebral blood flow with 99m-Tc-ECD using the aortic activity as arterial input estimate. K Van Laere, C Van de Wiele, Y Van Belle, K Audenaert, RA Dierckx Nucl Med Comm 1999, 20: 33-40 99mTc-sestamibi imaging in pediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein B De Moerloose, C Van de Wiele, C Dhooge, J Philippé, F Speleman, Y Benoit, G Laureys, RA Dierckx Eur J Nucl Med 1999; 26: 396-403 Laparoscopic adjustable silicone gastric banding leakage assessed using 99mTc- Pertechnetate scintigraphy: a report of three cases AC Van den Eeckhaut, G Villeirs, C Van de Wiele, J Versijpt, P Pattyn, RA Dierckx J Nucl Med 1999; 40: 783-785 MRI-SPECT and SPECT-SPECT brain co-registration: evaluation of the performance of eight different algorithms M Koole, Y D’Asseler, R Van de Walle, C Van de Wiele, I Lemahieu, RA Dierckx Nucl Med Comm 1999; 20 : 659-669 Biodistribution and dosimetry of (123-iodine)-iodomethyl-N, N diethyltamoxifen: an (anti)oestrogen receptor radioligand C Van de Wiele, F De Vos, J De Sutter, F Dumont, G Slegers, RA Dierckx, H Thierens Eur J Nucl Med 1999; 26: 1259-1264 Reverse redistribution on Thallium-201 SPECT after primary angioplasty: a one year follow-up study J De Sutter, C Van de Wiele, RA Dierckx, P Gheeraert, M De Buyzere, Y Taeymans Eur J Nucl Med 1999; 26: 633-636. QT dispersion is not related to infarct size or inducibility in patients with coronary artery disease and life-threatening ventricular arrhythmias J De Sutter, R Tavernier, C Van de Wiele, J De Backer, J Kazmierczak, G De Backer, RA Dierckx Heart 1999; 81: 533-538. The Selvester 32-point QRS-score for evaluation of myocardial infarct size after primary coronary angioplasty J De Sutter , C Van de Wiele, M De Buyzere , Y Taeymans , RA Dierckx, G De Backer, DL Clement Am J Cardiol 1999; 83: 255-257. Predictive value of Tc-99m DTPA captopril scintigraphy in patients with a solitary kidney and reduced kidney function. C. Van de Wiele, B Brans, R Vanholder, H Hoeben, K Van Laere, RA Dierckx Nucl Med Comm; 1999; 20: 263-266. Urinary excretion of tubular proteins, albumin, n-aceyl--D-glucosaminidase and the Tc-99m DMSA absolute renal uptake in partial ureteral obstruction in rats: a functional evaluation of hydronephrotic kidneys K Everaert, C Van de Wiele, J Delanghe, H Vander Eecken, JP Van Haelst, J Ouyand, J Van de Voorde, RA Dierckx, W Oosterlinck Urol Res1999; 27 (2): 127-131. Absolute 24h DMSA quantification in patients with severely reduced kidney function: a comparison with 51Cr-EDTA clearance. C Van de Wiele, A Van den Eeckhaut, W Verweire, JP Van Haelst, J Versypt, RA Dierckx Nucl Med Comm 1999; 20: 829-832. Estimation of risk based on biological dosimetry for patients treated with radioiodine M Monsieurs, HM Thierens, C Van de Wiele, AM Vral, IA Meirlaen, HA De Winter, CJ De Sadeleer, LI De Ridder, JM Kaufman, RA Dierckx Nucl Med Comm 1999; 20: 911-917. Adaptive response in patients treated with 131I MA Monsieurs, HM Thierens, AM Vral, C Van de Wiele, LI De Ridder, RA Dierckx J Nucl Med 1999; 41: 17-22. Visualisation of the stomach on Re-186 HEDP imaging after therapy for metastasized prostate carcinoma. F De Winter, B Brans, C Van de Wiele, RA Dierckx Clin Nucl Med 1999; 24: 898-899. Synthesis of 123I iodoaminogluthetimide, a possible radioligand for the visualisation of the aromatase enzyme in breast carcinoma by SPECT F De Vos, C Van de Wiele, G Slegers and RA Dierckx J labelled compd rad 1998; XL: 375-376 Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo. B Brans, G Laureys, V Schelfhout, C Van de Wiele, CR De Potter, C Dhooge, M Simons, RA Dierckx Eur J Nucl Med 1998; 25: 144-149 A SPECT study to compare Cobalt-57 and Technetium-99m-HMPAO-labeled leukocytes for visualisation of ischemic infarcts. H Stevens, C Van de Wiele, P Santens, HML Jansen, J De Reuck, RA Dierckx, J Korf. J Nucl Med 1998; 39: 495-498 Cobalt-57 as a SPECT-tracer in the visualisation of ischemic brain damage in patients with middle cerebral artery stroke H Stevens, S Knollema, DA Piers, C Van de Wiele, HML Jansen, AEJ De Jager, J De Reuck, RA Dierckx, J Korf Nucl Med Comm 1998; 19: 573-580 Age and gender related 24 hours DMSA uptake in children with normal DMSA scintigrams C Van de Wiele, M Simons, J Van de Walle, J De Sutter, K Everaert, RA Dierckx Nucl Med Comm 1998; 19: 149-154. Optimizing background correction when calculating differential renal function in the presence of hydroureteronephrosis using 99mTc-DTPA. C Van de Wiele, C De Sadeleer, M Koole, Y D’Asseler, K Everaert and RA Dierckx Nucl Med Comm, 1998; 19: 251-255. Urinary alpha 1 microglobulin detects uropathy. A prospective study in 483 patients K. Everaert, J Delanghe, C Van de Wiele, P Hoebeke, RA Dierckx, N Lameire, W Oosterlinck Clin Chem Lab Med, 1998; 36 (5): 309-315. Elevated tubular proteinuria, albuminuria and decreased urinary N-acetyl--D-glucosaminidase activity following unilateral total ureteral obstruction in rats. K Everaert, W Kerckhaert, J Delanghe, N Lameire, W Sturley, C Van de Wiele, RA Dierckx, J van de Voorde and W Oosterlinck. Urol Res 1998, 26: 285-289. The combined use of urinary -1-microglobuline and Tc-99m DMSA scintigraphy limits irradiation and costs in the diagnosis and follow-up of acute pyelonefritis and cystitis in children K Everaert, A Raes, P Hoebeke, W Samijn, J Delanghe, C Van de Wiele, J Van de Walle Eur Urol 1998, 475: 1-5. Thallium-201 scintigraphy does not allow visualisation of the thyroid in euthyroid and hyperthyroid patients treated with amiodarone C Van de Wiele, K Osmanagaoglu, M Monsieurs, K Van Laere, JM Kaufman, RA Dierckx Nucl Med Comm 1997; 18 : 513-516 Differential renal function measured by Tc-99m DTPA and Tc-99m DMSA in a complete unilateral renal obstruction rat model C Van De Wiele, K Everaert, H Van der Eecken, JP Van Haelst, M Simons, RA Dierckx Nucl Med Comm 1997; 18: 1036-1039. Aseptic necrosis : a scintigraphic imitator of osseous involvement in Ga-67 avid lymphoma C Van De Wiele, RA Dierckx, L Noens, M Simons Clin Nucl Med 1997; 22: 101-103. Delayed epiphyseal closure attributable to androgen deficiency C Van de Wiele, K Osmanagaoglu, K Audenaert, RA Dierckx Clin Nucl Med 1997; 22: 567-568. Decreased chemotaxis of lymphocytes labelled withTc-99m HMPAO is possibly related to apoptosis C Van de Wiele, J Philippé, JP Van Haelst, J Van Damme, H Thierens, GE Leroux-Roels, RA Dierckx J Nucl Med 1997; 38: 1417-1421. Comparison of bone scintigraphy, clinical findings and X-rays of the hands at the time of diagnosis in patients suffering from systemic lupus erythematosus and rheumatoid arthritis C Van De Wiele, F Van den Bosch, H Mielants, M Simons, E Veys, RA Dierckx J Rheumatol 1997; 97: 1916-1921. Gallium-67 and Technetium-99m-MDP scintigraphy for the detection and follow-up of osseous involvement in Ga-67 avid lymphoma C Van de Wiele, RA Dierckx, M Simons, L Noens J Nucl Med 1996, 37-13 : 548 Does leucocyte scintigraphy answer the need for a more widely available radiopharmaceutical that can detect and assess the proliferative state of lymphoma ? C Van de Wiele, M Simons, L Noens, RA Dierckx Eur J Nucl Med 1996; 23 : 471-473 Whole-body bone scan findings in X-linked hypophosphatemia C Van de Wiele, RA Dierckx, L Weynants, M Simons, JM Kaufman Clin Nucl Med 1996; 21: 483. Lymphocyte labelling with Tc-99m HMPAO : a radiotoxicity study using the micronucleus assay HMA Thierens, AM Vral, JP Van Haelst, C Van de Wiele, KHG Schelstraete, LF De Ridder J Nucl Med 1992; 33: 1167-1174.

Filtres : Toutes les années 2015 2013 2012 2011 2009 2008 2006 2005 2004 2003 2002 2001 1999 1997 1996

publications dans les journaux sans facteurs d'impact

publications dans les livres

éditeur de livres